CD30 has a co-stimulatory, mitogenic and activation effects on T cells.55 CD30 is also expressed with variable intensity on 36%56 to 50%57 of patient AML and its expression is associated with FLT-3-ITD mutations and leucocytosis.57 Upon cleavage from the extracellular domain, CD30 is released as a soluble form that can be detected in the blood of patients with Hodgkin and non-Hodgkin lymphoma and it is associated with poorer prognosis.58, 59 A TandAb containing two binding sites for CD30 and CD16A has been generated. Here, FLT3 is linked to acute myeloid leukemia.